Delivery Order SPE2DB20D3505-SPE2DB21FU3A3
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $7,085.03 for the pharmaceutical product Ciproflox-Dexameth Otic Suspension (7.5 ml). The award was made by the Defense Logistics Agency (DLA), a component of the Department of Defense, and does not have a set-aside designation, indicating open competition. Amerisourcebergen, a major pharmaceutical distributor, holds a significant $999,999,999 Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $1,588.37 to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., to provide Ciproflox-Dexameth Otic Suspension 7.5ML. This is a Firm Fixed Price contract with no set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor that holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $3,140.36, is for the delivery of Ciproflox-Dexameth Otic Suspension, a pharmaceutical product, with a performance period ending on July 26, 2022. The contract is a Delivery Order under a Firm Fixed Price arrangement, with no set-aside designation. Amerisourcebergen Drug Corp, a major pharmaceutical distributor,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Ciprofloxacin-Dexamethasone Otic Suspension, a specialty pharmaceutical product, for a total ceiling value of $1,490.75. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to deliver a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Ciproflox-Dexameth Otic Suspension, a pharmaceutical product. The contract has a ceiling value of $1,105.36 and runs through June 13, 2023. This is a firm fixed-price delivery order contract, and there was no set-aside designation used. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, holds a significant Indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,755.52, is for the delivery of Ciproflox-Dexameth Otic Suspension, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a completion date of February 22, 2023. The contract was not set aside for any specific business type. Amerisourcebergen holds a $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $2,704.96, is for the delivery of Ciproflox-Dexameth Otic Suspension, a medical product used for various therapeutic purposes. The contract is a Delivery Order type with a Firm Fixed Price pricing structure. It does not have a set-aside designation, indicating open competition. Amerisourcebergen...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $9,073.43 for the supply of CIPROFLOX-DEXAMETH OTIC SUSP 7.5ML. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of March 10, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies, particularly the Department...
- This federal contract award to Amerisourcebergen Drug Corp is a delivery order valued at $1,227.69 for the supply of Ciproflox-Dexameth Otic Suspension 7.5ML, a pharmaceutical product. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 21, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,155.11 for the supply of CIPROFLOX-DEXAMETH OTIC SUSP 7.5ML to the Defense Logistics Agency (DLA). The award has an ultimate completion date of May 2, 2023 and utilizes a firm fixed price contract type. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB21FU3A3Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order valued at $11,026.53 for the supply of Ciproflox-Dexameth Otic Suspension, a pharmaceutical product. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.0k | 7/28/21 |